For decades, Kweichow Moutai has served as the undisputed gold standard of Chinese profitability. The luxury baijiu distiller’s 91.18% gross margin was long considered an impenetrable ceiling for A-share listed companies. However, the release of 2025 annual reports reveals a shifting economic landscape where 23 companies, primarily in the biotechnology and high-tech sectors, have officially surpassed the liquor giant in margin efficiency.
At the pinnacle of this list are innovative oncology firms like Haihe Biopharma and Shouyao Holdings, which reported gross margins exceeding 98%. These figures reflect a structural shift in the Chinese market toward high-value intellectual property. While Moutai relies on brand equity and traditional craftsmanship, these biotech pioneers are capitalizing on breakthroughs in drug development and international licensing deals, signaling the maturation of China’s life sciences ecosystem.
The biotech surge is exemplified by the 'out-licensing' trend, where domestic firms sell global rights for their innovations to multinational giants. 3SBio, for instance, saw its revenue climb to 4.2 billion yuan following a massive $6 billion deal with Pfizer. This influx of capital has transformed the balance sheets of many R&D-heavy firms, turning long-term technical debt into immediate cash windfalls, even as some continue to report net losses due to ongoing clinical trial expenses.
Beyond medicine, the artificial intelligence and semiconductor sectors are carving out similar high-margin niches. Moore Threads, a rising star in the domestic AI chip space, reported a 243% revenue surge in 2025. Although it remains in the red, the narrowing of its losses and the expansion of its margins highlight the aggressive scaling of China’s computing infrastructure. These firms represent a strategic pivot toward 'New Quality Productive Forces,' a key policy priority in Beijing.
Despite the high-margin headlines, the data also suggests a recovery in the broader real economy. Over 2,600 listed companies reported simultaneous growth in both revenue and operating cash flow, a critical metric for financial health. While traditional sectors like steel and transportation lag with margins below 10%, the overall resilience of the industrial sector indicates that Chinese firms are becoming leaner and more focused on cash-generative operations after years of volatility.